PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
ROIV vs. RXRX
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between ROIV and RXRX is 0.37, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.4

Performance

ROIV vs. RXRX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Roivant Sciences Ltd. (ROIV) and Recursion Pharmaceuticals, Inc. (RXRX). The values are adjusted to include any dividend payments, if applicable.

-30.00%-20.00%-10.00%0.00%10.00%AugustSeptemberOctoberNovemberDecember2025
-1.60%
-23.12%
ROIV
RXRX

Key characteristics

Sharpe Ratio

ROIV:

0.00

RXRX:

-0.49

Sortino Ratio

ROIV:

0.24

RXRX:

-0.32

Omega Ratio

ROIV:

1.03

RXRX:

0.96

Calmar Ratio

ROIV:

0.00

RXRX:

-0.49

Martin Ratio

ROIV:

0.01

RXRX:

-0.90

Ulcer Index

ROIV:

7.36%

RXRX:

47.20%

Daily Std Dev

ROIV:

30.68%

RXRX:

85.89%

Max Drawdown

ROIV:

-79.22%

RXRX:

-88.97%

Current Drawdown

ROIV:

-18.12%

RXRX:

-84.47%

Fundamentals

Market Cap

ROIV:

$7.96B

RXRX:

$2.47B

EPS

ROIV:

$5.54

RXRX:

-$1.54

Total Revenue (TTM)

ROIV:

$88.54M

RXRX:

$54.29M

Gross Profit (TTM)

ROIV:

$78.10M

RXRX:

$14.55M

EBITDA (TTM)

ROIV:

$4.71B

RXRX:

-$262.33M

Returns By Period

In the year-to-date period, ROIV achieves a -6.42% return, which is significantly lower than RXRX's -5.03% return.


ROIV

YTD

-6.42%

1M

-8.51%

6M

-1.60%

1Y

1.93%

5Y*

N/A

10Y*

N/A

RXRX

YTD

-5.03%

1M

-13.71%

6M

-23.11%

1Y

-40.33%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

ROIV vs. RXRX — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ROIV
The Risk-Adjusted Performance Rank of ROIV is 4444
Overall Rank
The Sharpe Ratio Rank of ROIV is 4747
Sharpe Ratio Rank
The Sortino Ratio Rank of ROIV is 4141
Sortino Ratio Rank
The Omega Ratio Rank of ROIV is 4040
Omega Ratio Rank
The Calmar Ratio Rank of ROIV is 4848
Calmar Ratio Rank
The Martin Ratio Rank of ROIV is 4848
Martin Ratio Rank

RXRX
The Risk-Adjusted Performance Rank of RXRX is 2424
Overall Rank
The Sharpe Ratio Rank of RXRX is 2121
Sharpe Ratio Rank
The Sortino Ratio Rank of RXRX is 2525
Sortino Ratio Rank
The Omega Ratio Rank of RXRX is 2727
Omega Ratio Rank
The Calmar Ratio Rank of RXRX is 1818
Calmar Ratio Rank
The Martin Ratio Rank of RXRX is 2929
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

ROIV vs. RXRX - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Roivant Sciences Ltd. (ROIV) and Recursion Pharmaceuticals, Inc. (RXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for ROIV, currently valued at 0.00, compared to the broader market-2.000.002.000.00-0.49
The chart of Sortino ratio for ROIV, currently valued at 0.24, compared to the broader market-4.00-2.000.002.004.000.24-0.32
The chart of Omega ratio for ROIV, currently valued at 1.03, compared to the broader market0.501.001.502.001.030.96
The chart of Calmar ratio for ROIV, currently valued at 0.00, compared to the broader market0.002.004.006.000.00-0.57
The chart of Martin ratio for ROIV, currently valued at 0.01, compared to the broader market-30.00-20.00-10.000.0010.0020.000.01-0.90
ROIV
RXRX

The current ROIV Sharpe Ratio is 0.00, which is higher than the RXRX Sharpe Ratio of -0.49. The chart below compares the historical Sharpe Ratios of ROIV and RXRX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.500.000.501.00AugustSeptemberOctoberNovemberDecember2025
0.00
-0.49
ROIV
RXRX

Dividends

ROIV vs. RXRX - Dividend Comparison

Neither ROIV nor RXRX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

ROIV vs. RXRX - Drawdown Comparison

The maximum ROIV drawdown since its inception was -79.22%, smaller than the maximum RXRX drawdown of -88.97%. Use the drawdown chart below to compare losses from any high point for ROIV and RXRX. For additional features, visit the drawdowns tool.


-70.00%-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%AugustSeptemberOctoberNovemberDecember2025
-18.12%
-70.63%
ROIV
RXRX

Volatility

ROIV vs. RXRX - Volatility Comparison

The current volatility for Roivant Sciences Ltd. (ROIV) is 10.90%, while Recursion Pharmaceuticals, Inc. (RXRX) has a volatility of 29.59%. This indicates that ROIV experiences smaller price fluctuations and is considered to be less risky than RXRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%25.00%30.00%35.00%40.00%AugustSeptemberOctoberNovemberDecember2025
10.90%
29.59%
ROIV
RXRX

Financials

ROIV vs. RXRX - Financials Comparison

This section allows you to compare key financial metrics between Roivant Sciences Ltd. and Recursion Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab